ONO-9517601 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.067 μM, TREK-2 IC50= 0.23 μM). ONO-9517601 displays robust efficacy in an MK-801) challenge rat novel object recognition (NOR) paradigm. ONO-9517601 can be used for research on neurological and cognitive disorders.

ONO-7927846 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.11 μM, TREK-2 IC50= 0.29 μM). ONO-7927846 displays robust efficacy in an MK-801) challenge rat novel object recognition (NOR) paradigm. ONO-7927846 can be used for research on neurological and cognitive disorders.

MJ-26 is an inhibitor targeting Menin. MJ-26 has high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML). MJ-26 can be used in AML research.

FLT3/JAK2/BRD4 ligand-1 is a FLT3/JAK2/BRD4 ligand. FLT3/JAK2/BRD4 ligand-1 can be used for synthesis PROTAC FLT3/JAK2/BRD4 Degrader-1.

AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder.

Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ).

AF151 is a METTL3 PROTAC degrader with the DC50 of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading METTL3 protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML).

(S,R,S)-AHPC-CO-C2-phenylboronic acid is an E3 ligase ligand-linker conjugate that incorporates the VH032-based VHL ligand and linker. (S,R,S)-AHPC-CO-C2-phenylboronic acid can be used for synthesis of PROTAC AF151.

IA107 is a potent, selective, and allosteric IRE1α RNase (IC50 = 16 nM (non phosphorylated), IC50 = 9 nM (phosphorylated)) inhibitor. IA107 can inhibit endoplasmic reticulum stress-induced XBP1 mRNA splicing and protein expression, and has no cytotoxicity.

FB231 is a Parkin activator. FB231 can induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response. FB231 can lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. FB231 can cause activation of the integrated stress response (ISR) and perturbation to iron-dependent pathways. FB231 can be used for the research of neurological disease, such as Parkinson’s disease.

ML-93 is an orally active SAE inhibitor, with an IC50 value of 0.4 μM. ML-93 inhibits the SUMOylation pathway in HCT116 cells. ML-93 shows robust antitumor activity in the HCT116 colorectal carcinoma xenograft model. ML-93 can be used for the study of colorectal cancer.

VU6002703 (Compound 17) is a BBB-penetrable M4 mAChR positive allosteric modulator (PAM) with an EC50 of 0.6  μM for hM4. VU6002703 can be used for neuropsychiatric and rare genetic CNS disorders research.

CPI-203-PEG1-C3-O-COOH is a conjugate of the BRD4 ligand and the linker. CPI-203-PEG1-C3-O-COOH can be used for synthesizing PROTAC BRD4 degrader ARV-771

WML-01 is a fungicide with EC50s of 0.079, 0.72 and 2.02 μg/mL against F. graminearum, F. fujikuroi and S. sclerotiorum. WML-01 disrupts the cell membrane of F. graminearum and induces deposition of lipid droplets. WML-01 inhibits Deoxynivalenol (DON) biosynthesis with no cross-resistance and strongly suppresses ribosomal subunit assembly, impairing protein synthesis. WML-01 effectively controls the fusarium head blight (FHB) epidemic.

Y502-2304 is a c-Myc G-quadruplex stabilizer. Y502-2304 exhibits potent antiproliferative activity in multiple myeloma (MM) cells. Y502–2304 downregulates c-Myc mRNA and protein expression. Y502-2304 induces apoptosis in MM cells, characterizes by elevated γH2AX levels, increases reactive oxygen species (ROS) generation, and mitochondrial dysfunction. Y502-2304 significantly inhibits tumor growth in a xenograft MM model. Y502-2304 can be used for the study of multiple myeloma.

T-0902611 benzenesulfonate is a specific HCMV inhibitor. T-0902611 benzenesulfonate targets and covalently modifies the HCMV helicase–primase complex. T-0902611 benzenesulfonate can be used in the research of HCMV infection.

JY-21 is a BRD4 PROTAC degrader with a DC50 of 3.797 μM. JY-21 has a potent anticancer activity against MDA-MB-231 cells.

Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity.

CTC 96 is an antiviral agent, showing inhibitory effects particularly on herpes viruses and adenoviruses. CTC 96 directly blocks the fusion process between the viral envelope and the cell membrane, preventing the entry of viral nucleic acids and proteins into the cells. CTC 96 can completely block the penetration and intercellular transmission of HSV-1, preventing the synthesis of viral proteins and mRNA. CTC 96 exhibits significant anti-adenovirus activity in rabbit eye models. CTC 96 is also effective against varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV). CTC 96 can be used for broad-spectrum antiviral research.

KRAS G12D ligand-Linker Conjugate 2 is a conjugate of the KRAS (G12D) ligand and the linker. KRAS G12D ligand-Linker Conjugate 2 can be used for synthesizing PROTAC KRAS (G12D) degrader ASP-3082

JNJ627 is a small molecule allosteric inhibitor of IL-17A with a KD of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC50 value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis).

afi-FSP1-1 is a Ferroptosis suppressor protein 1 (FSP1) inhibitor with an Ki of 0.283  μM. afi-FSP1-1 has a superior binding capacity to FSP1-FAD-NAD+. afi-FSP1-1 can induces ferroptosis in cancer cells. afi-FSP1-1 can be used for cancers research.

SHP2 ligand-3 is a PROTAC target protein ligand that can be used to synthesize SHP2 protein degrader-1.

Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a Ki of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure.

4-(4-Boc-piperazinemethyl)phenylboronic acid pinacol ester is a PROTAC linker that can be used in the synthesis of CST905.

Chem-0199 is an Adipocyte Enhancer-Binding Protein 1 (AEBP1) inhibitor. Chem-0199 can disrupt the interaction between AEBP1 and CKAP4, thereby enhances antitumor immunity. Chem-0199 can inhibit Akt phosphorylation (p-Akt) and downregulates PD-L1 expression. Chem-0199 can be used for the research of cancer, such as colon cancer.

YM 934 is a potassium channel opener. YM 934 inhibits neurogenic plasma leakage. YM 934 inhibits airway neurogenic inflammation.

SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model.

BMS-188184 is a type II s-PLA2 inhibitor (IC50 = 17 µM). BMS-188184 can be used for research on inflammatory conditions.

Melianol is a compound that can be extracted from the fruits of Melia azeradacha and can be used as an acaricide.